For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | |
|---|---|---|---|---|
| License revenue | - | 200* | - | |
| Research and development | 5,961 | -18,749* | 15,558 | |
| General and administrative | 6,118 | -12,382* | 11,036 | |
| Total operating expenses | 12,079 | -31,131* | 26,594 | |
| Gain from operations | -12,079 | 31,331* | -26,594 | |
| Interest income (expense) | 1,129 | 2,323* | -96 | |
| Other income (expense), net | 341 | -4,794* | 1,837 | |
| Total other income (expense), net | 1,470 | -2,471* | 1,741 | |
| Gain before income taxes | -10,609 | 28,860* | -24,853 | |
| Income tax expense | 10 | -128* | -74 | |
| Net gain | -10,619 | 28,988* | -24,779 | |
| Accretion of redeemable convertible preferred shares | - | 4,508* | 846 | |
| Net gain attributable to common stockholders | -10,619 | 24,480 | -25,625 | |
| Basic EPS | -0.95 | 20.148 | -2.91 | |
| Diluted EPS | -0.95 | 20.148 | -2.91 | |
| Basic Average Shares | 11,211,268 | 1,215,031 | 8,526,781 | |
| Diluted Average Shares | 11,211,268 | 1,215,031 | 8,526,781 | |
ImageneBio, Inc. (IMA)
ImageneBio, Inc. (IMA)